Glenmark Pharma launches nasal spray for Covid-19 treatment of high-risk adult patients in India

Glenmark Pharmaceuticals Ltd, in collaboration with Canadian pharmaceutical company SaNOtize, announced the launch of a nitric oxide nasal spray called ‘FabiSpray’ in India on Wednesday.

FabiSpray has been developed for the treatment of adult patients of Covid-19 who have a high risk of progression of the disease. This includes non-vaccinated patients, patients in the middle and older age group and patients with co-morbidities.

The company had earlier received manufacturing and marketing approval for FabiSpray from the Drugs Controller General of India (DCGI) as part of the accelerated approval process.

Robert Crockart, chief commercial officer at Glenmark, said on the development, “As a leading pharmaceutical player, it is important that we are an integral part of India’s fight against the Covid-19 pandemic. We are confident it will offer patients a much needed and timely therapy option.”

HOW DOES IT WORK?

FabiSpray, according to Glenmark, is designed to kill the Covid-19 virus in the upper airways. It has proven anti-microbial properties.

When sprayed over nasal mucosa, it acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs, the pharmaceutical company explained.

PHASE 3 TRIAL OUTCOME

The Phase 3 trials of the spray in India demonstrated reduction of viral load by 94 per cent in 24 hours and 99 per cent in 48 hours.

The spray was safe and well-tolerated by Covid patients.